Apalutamide for High-Risk Localized Prostate Cancer Following Radical Prostatectomy (Apa-RP)

Approximately 25 to 50% of patients with high-risk localized prostate cancer experience biochemical recurrence within 2 years of radical prostatectomy. The Apa-RP study (NCT04523207) investigated whether adjuvant apalutamide plus androgen deprivation therapy in high-risk patients who have undergone radical prostatectomy improved biochemical recurrence-free survival.